Nephrotic Syndrome Market Analysis: Epidemiology Insights, Therapies, Companies, DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers

The Nephrotic Syndrome Treatment Market Size in the 7MM reached approximately USD 401 million in 2022. Projections indicate a substantial growth during the forecast period.

Nephrotic Syndrome treatments, including therapies like Atacicept, Atrasentan, and others, are anticipated to drive growth in the Nephrotic Syndrome market in the coming years.

DelveInsight has released a new report titled "Nephrotic Syndrome - Market Insights, Epidemiology, and Market Forecast-2034," providing a comprehensive analysis of Nephrotic Syndrome, including historical and projected epidemiology, as well as market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Nephrotic Syndrome market report @ https://www.delveinsight.com/report-store/nephrotic-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Nephrotic Syndrome Market Report:

*
The Nephrotic Syndrome market is anticipated to grow steadily over the forecast period (2023-2034), driven largely by the introduction of novel therapies.

*
DelveInsight's analysis indicates that the United States accounted for approximately 34% of all diagnosed Nephrotic Syndrome cases in the 7MM. In 2022, the EU4 and the UK collectively reported around 367,000 diagnosed cases.

*
In the 7MM, the Nephrotic Syndrome drugs market primarily consisted of corticosteroids, calcineurin inhibitors, ACE inhibitors/ARBs, immunosuppressants, and other treatments, generating an estimated USD 401 million in 2022. Market growth is expected to accelerate with the arrival of new and effective therapies, including Atacicept, Atrasentan, Gazyva/Gazyvaro (obinutuzumab), Zigakibart (BION-1301), and others.

*
Notable recent developments include the FDA's March 2025 expansion of Furoscix's approval to treat edema in patients with chronic kidney disease, including those with Nephrotic Syndrome. This furosemide injection (Furoscix; scPharmaceuticals, Inc.) is expected to be available by April 2025 after the FDA accepted its supplemental new drug application in July 2024.

*
In January 2025, Hoffmann-La Roche launched an open-label, randomized multicenter study evaluating obinutuzumab versus mycophenolate mofetil (MMF) in children and young adults (ages 2-25) with frequently relapsing or steroid-dependent Nephrotic Syndrome, assessing efficacy, safety, and pharmacokinetics/pharmacodynamics.

*
According to DelveInsight, the total diagnosed prevalent cases of Nephrotic Syndrome in the 7MM were approximately 786,000 in 2022, with numbers expected to increase over the forecast period. In the United States alone, around 268,000 individuals were diagnosed in 2022, with continued growth projected at an estimated CAGR through 2034.

*
Leading companies advancing treatments for Nephrotic Syndrome include GlaxoSmithKline, Goldfinch Bio, Travere Therapeutics, Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others. Promising therapies under development include Atacicept, Atrasentan, and additional novel candidates.

Nephrotic Syndrome Overview

Nephrotic Syndrome is a medical condition marked by significant protein loss in the urine (proteinuria), which leads to low levels of albumin in the blood (hypoalbuminemia) and subsequently causes complications such as hyperlipidemia, edema, and other related issues. It can develop due to various underlying causes, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, lupus nephritis, diabetic nephropathy, infections, genetic disorders, certain medications, and more. Chronic cases of nephrotic syndrome may result in additional complications, such as increased susceptibility to infections, malnutrition, and elevated cardiovascular risk. Identifying the underlying cause is therefore essential for effective management and treatment.

Pathologically, nephrotic syndrome is characterized by structural and functional alterations in the glomeruli-the kidney's filtration units responsible for removing waste and excess fluids from the blood. A key feature is increased permeability of the glomerular filtration barrier, leading to significant protein loss, particularly albumin, through the urine.

Nephrotic Syndrome Market Outlook

Nephrotic Syndrome is a medical condition marked by significant protein loss in the urine (proteinuria), which leads to low levels of albumin in the blood (hypoalbuminemia) and subsequently causes complications such as hyperlipidemia, edema, and other related issues. It can develop due to various underlying causes, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, lupus nephritis, diabetic nephropathy, infections, genetic disorders, certain medications, and more. Chronic cases of nephrotic syndrome may result in additional complications, such as increased susceptibility to infections, malnutrition, and elevated cardiovascular risk. Identifying the underlying cause is therefore essential for effective management and treatment.

Pathologically, nephrotic syndrome is characterized by structural and functional alterations in the glomeruli-the kidney's filtration units responsible for removing waste and excess fluids from the blood. A key feature is increased permeability of the glomerular filtration barrier, leading to significant protein loss, particularly albumin, through the urine.

Discover how the Nephrotic Syndrome market is rising in the coming years @ https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Nephrotic Syndrome Emerging Drugs

*
Atacicept: Vera Therapeutics

*
Atrasentan: Chinook Therapeutics/ Novartis

Scope of the Nephrotic Syndrome Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Nephrotic Syndrome Companies: GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others

*
Key Nephrotic Syndrome Therapies: Atacicept, Atrasentan and others

*
Nephrotic Syndrome Therapeutic Assessment: Nephrotic Syndrome current marketed and Nephrotic Syndrome emerging therapies

*
Nephrotic Syndrome Market Dynamics: Nephrotic Syndrome market drivers and Nephrotic Syndrome market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Nephrotic Syndrome Unmet Needs, KOL's views, Analyst's views, Nephrotic Syndrome Market Access and Reimbursement

To know what's more in our Nephrotic Syndrome report, visit https://www.delveinsight.com/report-store/nephrotic-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Nephrotic Syndrome Market Report:

*
Nephrotic Syndrome market report covers a descriptive overview and comprehensive insight of the Nephrotic Syndrome Epidemiology and Nephrotic Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Nephrotic Syndrome market report provides insights into the current and emerging therapies.

*
The Nephrotic Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Nephrotic Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Nephrotic Syndrome market.

Got queries? Click here to know more about the Nephrotic Syndrome market Landscape [https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Nephrotic Syndrome Patient Share (%) Overview at a Glance

5. Nephrotic Syndrome Market Overview at a Glance

6. Nephrotic Syndrome Disease Background and Overview

7. Nephrotic Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Nephrotic Syndrome

9. Nephrotic Syndrome Current Treatment and Medical Practices

10. Unmet Needs

11. Nephrotic Syndrome Emerging Therapies

12. Nephrotic Syndrome Market Outlook

13. Country-Wise Nephrotic Syndrome Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Nephrotic Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Nephrotic Syndrome Market Outlook 2034 [https://www.delveinsight.com/report-store/nephrotic-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Nephrotic Syndrome Pipeline Insights, DelveInsight

"Nephrotic Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Nephrotic Syndrome market. A detailed picture of the Nephrotic Syndrome pipeline landscape is provided, which includes the disease overview and Nephrotic Syndrome treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nephrotic-syndrome-market-analysis-epidemiology-insights-therapies-companies-delveinsight-glaxosmithkline-goldfinch-bio-inc-travere-therapeutics-inc-aurinia-pharmaceuticals-bristolmyers]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.